Revolution Medicines, Inc. 42Z.F Stock
Revolution Medicines, Inc. Price Chart
Revolution Medicines, Inc. 42Z.F Financial and Trading Overview
| Revolution Medicines, Inc. stock price | 34.8 EUR |
| Previous Close | 23.2 EUR |
| Open | 22.8 EUR |
| Bid | 22.8 EUR x N/A |
| Ask | 23.2 EUR x N/A |
| Day's Range | 22.8 - 22.8 EUR |
| 52 Week Range | 15.9 - 27.6 EUR |
| Volume | 200 EUR |
| Avg. Volume | 5 EUR |
| Market Cap | 2.42B EUR |
| Beta (5Y Monthly) | 1.443588 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.17 EUR |
42Z.F Valuation Measures
| Enterprise Value | 1.62B EUR |
| Trailing P/E | N/A |
| Forward P/E | -8.382353 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 69.63312 |
| Price/Book (mrq) | 2.5452108 |
| Enterprise Value/Revenue | 46.538 |
| Enterprise Value/EBITDA | -5.974 |
Trading Information
Revolution Medicines, Inc. Stock Price History
| Beta (5Y Monthly) | 1.443588 |
| 52-Week Change | 47.16% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 27.6 EUR |
| 52 Week Low | 15.9 EUR |
| 50-Day Moving Average | 21.97 EUR |
| 200-Day Moving Average | 21.73 EUR |
42Z.F Share Statistics
| Avg. Volume (3 month) | 5 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 106.31M |
| Float | 99.12M |
| Short Ratio | N/A |
| % Held by Insiders | 1.72% |
| % Held by Institutions | 84.85% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -791.26% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.61% |
| Return on Equity (ttm) | -34.47% |
Income Statement
| Revenue (ttm) | 34.82M EUR |
| Revenue Per Share (ttm) | 0.41 EUR |
| Quarterly Revenue Growth (yoy) | -7.39% |
| Gross Profit (ttm) | -217693000 EUR |
| EBITDA | -271241984 EUR |
| Net Income Avi to Common (ttm) | -259156000 EUR |
| Diluted EPS (ttm) | -2.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 909.8M EUR |
| Total Cash Per Share (mrq) | 8.56 EUR |
| Total Debt (mrq) | 63.6M EUR |
| Total Debt/Equity (mrq) | 6.68 EUR |
| Current Ratio (mrq) | 16.889 |
| Book Value Per Share (mrq) | 8.958 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -231632000 EUR |
| Levered Free Cash Flow (ttm) | -138491376 EUR |
Profile of Revolution Medicines, Inc.
| Country | Germany |
| State | CA |
| City | Redwood City |
| Address | 700 Saginaw Drive |
| ZIP | 94063 |
| Phone | 650 481 6801 |
| Website | https://www.revmed.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 259 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Q&A For Revolution Medicines, Inc. Stock
What is a current 42Z.F stock price?
Revolution Medicines, Inc. 42Z.F stock price today per share is 34.8 EUR.
How to purchase Revolution Medicines, Inc. stock?
You can buy 42Z.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Revolution Medicines, Inc.?
The stock symbol or ticker of Revolution Medicines, Inc. is 42Z.F.
Which industry does the Revolution Medicines, Inc. company belong to?
The Revolution Medicines, Inc. industry is Biotechnology.
How many shares does Revolution Medicines, Inc. have in circulation?
The max supply of Revolution Medicines, Inc. shares is 164.69M.
What is Revolution Medicines, Inc. Price to Earnings Ratio (PE Ratio)?
Revolution Medicines, Inc. PE Ratio is now.
What was Revolution Medicines, Inc. earnings per share over the trailing 12 months (TTM)?
Revolution Medicines, Inc. EPS is -3.6 EUR over the trailing 12 months.
Which sector does the Revolution Medicines, Inc. company belong to?
The Revolution Medicines, Inc. sector is Healthcare.